{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T12:08:32Z","timestamp":1795090112885,"version":"4.10.2"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-026-04193-x","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T14:26:00Z","timestamp":1770387960000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic value of metastatic lymph-node ratio and log-odds of positive nodes after neoadjuvant chemotherapy in breast cancer"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6633-7691","authenticated-orcid":false,"given":"Eda","family":"G\u00fcner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9979-9662","authenticated-orcid":false,"given":"Serdar","family":"Sar\u0131demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2611-4837","authenticated-orcid":false,"given":"Cihangir","family":"\u00d6zaslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"issue":"3","key":"4193_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"4193_CR2","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1001\/jama.2011.90","volume":"305","author":"AE Giuliano","year":"2011","unstructured":"Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and Sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569\u201375. https:\/\/doi.org\/10.1001\/jama.2011.90.","journal-title":"JAMA"},{"key":"4193_CR3","doi-asserted-by":"publisher","unstructured":"Chen S, Liu Y, Huang L, Chen CM, Wu J, Shao ZM. Lymph node counts\u00a0and ratio in axillary dissections following neoadjuvant chemotherapy for breast cancer: a\u00a0better alternative to traditional pN staging. Ann Surg Oncol. 2014;21(1):42\u201350. https:\/\/doi.org\/10.1245\/s10434-013-3245-6.","DOI":"10.1245\/s10434-013-3245-6"},{"issue":"6","key":"4193_CR4","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1245\/s10434-018-6429-2","volume":"25","author":"TA Moo","year":"2018","unstructured":"Moo TA, Edelweiss M, Hajiyeva S, et al. Is low-volume disease in the sentinel node after neoadjuvant chemotherapy an indication for axillary dissection? Ann Surg Oncol. 2018;25(6):1488\u201394. https:\/\/doi.org\/10.1245\/s10434-018-6429-2.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"4193_CR5","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1001\/jamaoncol.2016.4163","volume":"3","author":"M Pilewskie","year":"2017","unstructured":"Pilewskie M, Morrow M. Axillary nodal management following neoadjuvant chemotherapy: a review. JAMA Oncol. 2017;3(4):549\u201355. https:\/\/doi.org\/10.1001\/jamaoncol.2016.4163.","journal-title":"JAMA Oncol"},{"key":"4193_CR6","doi-asserted-by":"publisher","unstructured":"Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, et al. Clinical significance of axillary nodal ratio in stage II\/III breast cancer treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 2009;116(1):153\u201360. https:\/\/doi.org\/10.1007\/s10549-008-0160-9.","DOI":"10.1007\/s10549-008-0160-9"},{"key":"4193_CR7","doi-asserted-by":"publisher","unstructured":"Liu J, Li Y, Zhang W, Yang C, Yang C, Chen L, Ding M, et al. The prognostic role of lymph node ratio in breast cancer patients received neoadjuvant chemotherapy: a dose-response meta-analysis. Front Surg. 2022;9:971030. https:\/\/doi.org\/10.3389\/fsurg.2022.971030.","DOI":"10.3389\/fsurg.2022.971030"},{"key":"4193_CR8","doi-asserted-by":"publisher","unstructured":"Tsai J, Bertoni D, Hernandez-Boussard T, Telli ML, Wapnir IL. Lymph node ratio analysis after neoadjuvant chemotherapy is prognostic in hormone receptor-positive and triple-negative breast cancer. Ann Surg Oncol. 2016;23(10):3310\u20136. https:\/\/doi.org\/10.1245\/s10434-016-5319-8.","DOI":"10.1245\/s10434-016-5319-8"},{"issue":"7","key":"4193_CR9","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1200\/JCO.2008.18.6965","volume":"27","author":"V Vinh-Hung","year":"2009","unstructured":"Vinh-Hung V, Verkooijen HM, Fioretta G, et al. Lymph node ratio as an alternative to pN staging in node-positive breast cancer. J Clin Oncol. 2009;27(7):1062\u20138. https:\/\/doi.org\/10.1200\/JCO.2008.18.6965.","journal-title":"J Clin Oncol"},{"key":"4193_CR10","doi-asserted-by":"publisher","unstructured":"Wen J, Ye F, He X, Li S, Huang X, Xiao X, et al. Development and validation of a prognostic nomogram based on the log odds of positive lymph nodes (LODDS) for breast cancer. Oncotarget. 2016;7(15):21046\u201353. https:\/\/doi.org\/10.18632\/oncotarget.8091.","DOI":"10.18632\/oncotarget.8091"},{"key":"4193_CR11","doi-asserted-by":"publisher","unstructured":"Chen LJ, Chung KP, Chang YJ, Chang YJ. Ratio and log odds of positive lymph nodes in breast cancer patients with mastectomy. Surg Oncol. 2015;24(3):239\u201347. https:\/\/doi.org\/10.1016\/j.suronc.2015.05.001.","DOI":"10.1016\/j.suronc.2015.05.001"},{"key":"4193_CR12","doi-asserted-by":"publisher","unstructured":"Vinh-Hung V, Verschraegen C, Promish DI, Cserni G, Van de Steene J, Tai P, et al. Ratios of involved nodes in early breast cancer. Breast Cancer Res. 2004;6(6):R680\u20138. https:\/\/doi.org\/10.1186\/bcr934.","DOI":"10.1186\/bcr934"},{"key":"4193_CR13","doi-asserted-by":"publisher","unstructured":"von Minckwitz G, Rezai M, Fasching PA, Huober J, Tesch H, Bauerfeind I, et al. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40-GeparQuattro). Ann Oncol. 2014;25(1):81\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdt410.","DOI":"10.1093\/annonc\/mdt410"},{"issue":"15","key":"4193_CR14","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1200\/JCO.2006.10.3523","volume":"25","author":"CA Hudis","year":"2007","unstructured":"Hudis CA, Barlow WE, Costantino JP, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol. 2007;25(15):2127\u201332. https:\/\/doi.org\/10.1200\/JCO.2006.10.3523.","journal-title":"J Clin Oncol"},{"key":"4193_CR15","doi-asserted-by":"publisher","unstructured":"Petrelli F, Viale G, Cabiddu M, Barni S. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients. Breast Cancer Res Treat. 2015;153(3):477\u201391. https:\/\/doi.org\/10.1007\/s10549-015-3559-0.","DOI":"10.1007\/s10549-015-3559-0"},{"issue":"4","key":"4193_CR16","doi-asserted-by":"publisher","first-page":"496","DOI":"10.20892\/j.issn.2095-3941.2016.0066","volume":"13","author":"NA Soliman","year":"2016","unstructured":"Soliman NA, Yussif SM. Ki-67 as a prognostic marker according to breast cancer molecular subtype. Cancer Biol Med. 2016;13(4):496\u2013504. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2016.0066.","journal-title":"Cancer Biol Med"},{"key":"4193_CR17","doi-asserted-by":"publisher","unstructured":"Liu D, Chen Y, Deng M, Xie G, Wang J, Zhang L, et al. Lymph node ratio and breast cancer prognosis: a meta-analysis. Breast Cancer. 2014;21(1):1\u20139. https:\/\/doi.org\/10.1007\/s12282-013-0497-8.","DOI":"10.1007\/s12282-013-0497-8"},{"key":"4193_CR18","doi-asserted-by":"publisher","unstructured":"He M, Zhang JX, Jiang YZ, Chen YL, Yang HY, Tang LC, et al. The lymph node ratio as an independent prognostic factor for node-positive triple-negative breast cancer. Oncotarget. 2017;8(27):44870\u201380. https:\/\/doi.org\/10.18632\/oncotarget.17413.","DOI":"10.18632\/oncotarget.17413"},{"key":"4193_CR19","doi-asserted-by":"publisher","unstructured":"Wu SG, Li Q, Zhou J, Sun JY, Li FY, Lin Q, et al. Using the lymph node ratio to evaluate the prognosis of stage II\/III breast cancer patients who received neoadjuvant chemotherapy and mastectomy. Cancer Res Treat. 2015;47(4):757\u201364. https:\/\/doi.org\/10.4143\/crt.2014.039.","DOI":"10.4143\/crt.2014.039"},{"key":"4193_CR20","doi-asserted-by":"publisher","unstructured":"De la Cruz-Ku G, Chambergo-Michilot D, Valcarcel B, Rebaza P, M\u00f6ller M, Araujo JM, et al. Lymph node ratio as best prognostic factor in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy. Breast J. 2020;26(9):1659\u201366. https:\/\/doi.org\/10.1111\/tbj.13988.","DOI":"10.1111\/tbj.13988"},{"key":"4193_CR21","doi-asserted-by":"publisher","unstructured":"Agarwal R, Philip A, Pavithran K, Rajanbabu A, Goel G, Vijaykumar DK. Prognostic significance of residual nodal burden using lymph node ratio in locally advanced breast cancer after neoadjuvant chemotherapy. Indian J Cancer. 2019;56(3):228\u201335. https:\/\/doi.org\/10.4103\/ijc.IJC_652_18.","DOI":"10.4103\/ijc.IJC_652_18"},{"key":"4193_CR22","doi-asserted-by":"publisher","unstructured":"Liu C, Li H, Zhuo R, Wang L, He L, Ruan Q, et al. Grade-lymph node ratio predicts the survival of breast cancer in different molecular types: a surveillance, epidemiology, and end results population-based analysis. Medicine (Baltimore). 2019;98(28):e16436. https:\/\/doi.org\/10.1097\/MD.0000000000016436.","DOI":"10.1097\/MD.0000000000016436"},{"key":"4193_CR23","doi-asserted-by":"publisher","unstructured":"Jin ML, Gong Y, Pei YC, Ji P, Hu X, Shao ZM. Modified lymph node ratio improves the prognostic predictive ability for breast cancer patients compared with other lymph node staging systems. Breast. 2020;49:93\u2013100. https:\/\/doi.org\/10.1016\/j.breast.2019.11.003.","DOI":"10.1016\/j.breast.2019.11.003"},{"key":"4193_CR24","unstructured":"Wu SG, Wang Y, Zhou J, Sun JY, Li FY, Lin HX, et al. Number of negative lymph nodes should be considered for incorporation into staging for breast cancer. Am J Cancer Res. 2015;5(2):844\u201353."},{"issue":"1","key":"4193_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-15209-z","volume":"15","author":"C Zheng","year":"2025","unstructured":"Zheng C, Huang J, Zhao S, et al. Log odds of positive lymph nodes as a prognostic marker in resectable triple-negative breast cancer. Sci Rep. 2025;15(1):30348. https:\/\/doi.org\/10.1038\/s41598-025-15209-z.","journal-title":"Sci Rep"},{"issue":"22","key":"4193_CR26","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147\u201359. https:\/\/doi.org\/10.1056\/NEJMoa1612645.","journal-title":"N Engl J Med"},{"key":"4193_CR27","doi-asserted-by":"publisher","unstructured":"Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer. Ann Oncol. 2022;33(12):1250\u201368. https:\/\/doi.org\/10.1016\/j.annonc.2022.09.159.","DOI":"10.1016\/j.annonc.2022.09.159"},{"issue":"25","key":"4193_CR28","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant Olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384(25):2394\u2013405. https:\/\/doi.org\/10.1056\/NEJMoa2105215.","journal-title":"N Engl J Med"},{"issue":"7","key":"4193_CR29","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1814017.","journal-title":"N Engl J Med"},{"key":"4193_CR30","doi-asserted-by":"publisher","unstructured":"von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377(2):122\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1703643.","DOI":"10.1056\/NEJMoa1703643"},{"key":"4193_CR31","doi-asserted-by":"publisher","unstructured":"Meng X, Hao F, Wang N, Qin P, Ju Z, Sun D. Log odds of positive lymph nodes (LODDS)-based novel nomogram for survival estimation in patients with invasive micropapillary carcinoma of the breast. BMC Med Res Methodol. 2024;24(1):90. https:\/\/doi.org\/10.1186\/s12874-024-02218-1.","DOI":"10.1186\/s12874-024-02218-1"},{"key":"4193_CR32","doi-asserted-by":"publisher","unstructured":"Saxena N, Hartman M, Yip CH, Bhoo-Pathy N, Khin LW, Taib NA, et al. Does the axillary lymph node ratio have any added prognostic value over pN staging for South East Asian breast cancer patients? PLoS One. 2012;7(9):e45809. https:\/\/doi.org\/10.1371\/journal.pone.0045809.","DOI":"10.1371\/journal.pone.0045809"},{"key":"4193_CR33","doi-asserted-by":"publisher","unstructured":"Denkert C, Liedtke C, Tutt A, von Minckwitz G. Molecular alterations in triple-negative breast cancer\u2014the road to new treatment strategies. Lancet. 2017;389(10087):2430\u201342. https:\/\/doi.org\/10.1016\/S0140-6736(16)32454-0.","DOI":"10.1016\/S0140-6736(16)32454-0"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-026-04193-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04193-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04193-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T14:27:37Z","timestamp":1781101657000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-026-04193-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4193"],"URL":"https:\/\/doi.org\/10.1186\/s12957-026-04193-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7557989\/v1","asserted-by":"object"}]},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"7 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been updated: references were updated.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approved by the Institutional Review Board of Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital (Decision No: 2025-06-90). Given the retrospective design, the requirement for individual informed consent was waived. Procedures complied with the Declaration of Helsinki (1975, as revised) and were approved by the institutional review board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This retrospective study was approved by the Institutional Review Board\/Ethics Committee of Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital (Approval No: 2025-06-90, Date: 22.06.2025). Given the retrospective design and use of de-identified data, the requirement for written informed consent was waived by the committee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"116"}}